Close Menu
World Economist – Global Markets, Finance & Economic Insights
  • Home
  • Economist Impact
    • Economist Intelligence
    • Finance & Economics
  • Business
  • Asia
  • China
  • Europe
  • Economy
  • USA
    • Middle East & Africa
    • Highlights
  • This week
  • World Economy
    • World News
What's Hot

Chinese scientists seek to unlock AI’s power to tackle real world problems

October 11, 2025

Asia eyes cheaper oil as Israel-Hamas ceasefire kindles hope for calm

October 11, 2025

Chinese local governments warned not to give AI access to sensitive data or state secrets

October 11, 2025
Facebook X (Twitter) Instagram
Saturday, October 11
Facebook X (Twitter) Instagram
World Economist – Global Markets, Finance & Economic Insights
  • Home
  • Economist Impact
    • Economist Intelligence
    • Finance & Economics
  • Business
  • Asia
  • China
  • Europe
  • Economy
  • USA
    • Middle East & Africa
    • Highlights
  • This week
  • World Economy
    • World News
World Economist – Global Markets, Finance & Economic Insights
Home » Citadel and Millennium outshone by smaller hedge fund rivals after trade war turmoil
USA

Citadel and Millennium outshone by smaller hedge fund rivals after trade war turmoil

adminBy adminJuly 1, 2025No Comments3 Mins Read
Share Facebook Twitter Pinterest Copy Link LinkedIn Tumblr Email VKontakte Telegram
Share
Facebook Twitter Pinterest Email Copy Link
Post Views: 54


Stay informed with free updates

Simply sign up to the Hedge funds myFT Digest — delivered directly to your inbox.

Hedge fund giants Citadel and Millennium have been outshone by smaller rivals so far this year, as the firms were stung by the market volatility unleashed by Donald Trump’s trade war.

Citadel’s flagship Wellington fund gained 2.5 per cent in the first half of 2025 while Millennium gained 2.2, according to people familiar with the matter. Balyasny and ExodusPoint were up 7.3 per cent and 9.3 per cent, respectively, according to people who have seen the figures.

Ken Griffin’s Citadel and Izzy Englander’s Millennium, which manage about $66bn and $75bn respectively, are the dominant players among so-called multi-manager funds, a sector that has sucked in billions of dollars from the world’s largest investors.

Multi-manager firms, which also include $25bn Balyasny and $11bn ExodusPoint, have legions of trading teams known as “pods”, which trade a variety of strategies in asset classes including equities, fixed income and commodities. They borrow large sums from banks to juice returns and adhere to strict risk management to control losses, making them attractive to big investors such as pension funds that desire stable returns.

As pioneers of the model, Millennium and Citadel have been catapulted to the very top of the hedge fund industry over the past decade.

Multi-managers are fuelled by so-called “pass-through” fees, which involve charging all expenses, including office rents, technology and data, bonuses and client entertainment, directly to investors. This is a departure from the typical hedge fund model, which historically charged a 2 per cent management fee on assets.

Citadel was wrongfooted by Trump’s tariff policies earlier this year, with Griffin telling The Economist in May that the firm had to “tear apart and re-examine the portfolio . . . and ask yourself in what ways we have positioned or mis-positioned ourselves against the reality that the odds of a recession have gone higher”.

Last year, Citadel and Millennium eclipsed most rivals as they delivered 15 per cent to investors. Citadel’s annualised net return since the firm was founded 35 years ago is roughly 19.2 per cent.

Griffin, a major Republican donor, has become one of Trump’s most outspoken critics, saying last year that the president’s tariff plans would put the US “on a slippery slope to crony capitalism”.

Meanwhile, the flagship Apex strategy of billionaire Cliff Asness’s quant fund AQR was up 11.4 per cent in the first half of the year, according to a person familiar with the numbers. Bridgewater Associates, the macro hedge fund founded by billionaire Ray Dalio, also had a strong first half of the year with its Pure Alpha fund returning 17 per cent.



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Telegram Copy Link
admin
  • Website

Related Posts

USA

Why Intel investors have embraced an interventionist White House

August 28, 2025
USA

Trump’s attack on the Fed threatens US credibility

August 27, 2025
USA

The next stage of the Fed takeover

August 27, 2025
USA

Surging US electricity prices put Trump pledge in jeopardy

August 27, 2025
USA

EU moves to shield aluminium from Trump tariff blow

August 27, 2025
USA

Donald Trump’s battle against the Fed heads for courtroom showdown

August 26, 2025
Add A Comment
Leave A Reply Cancel Reply

Editors Picks

Aurangzeb heads to US amid hopes of staff-level agreement – Business & Finance

October 11, 2025

KATI concerned over widening trade deficit – Business & Finance

October 11, 2025

Khairpur SEZ honoured among top industrial zones of Asia-Pacific – Business & Finance

October 11, 2025

Kuwait-Pakistan Expo 2025 to be held in Kuwait – Business & Finance

October 11, 2025
Latest Posts

PSX hits all-time high as proposed ‘neutral-to-positive’ budget well-received by investors – Business

June 11, 2025

Sindh govt to allocate funds for EV taxis, scooters in provincial budget: minister – Pakistan

June 11, 2025

US, China reach deal to ease export curbs, keep tariff truce alive – World

June 11, 2025

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Recent Posts

  • Chinese scientists seek to unlock AI’s power to tackle real world problems
  • Asia eyes cheaper oil as Israel-Hamas ceasefire kindles hope for calm
  • Chinese local governments warned not to give AI access to sensitive data or state secrets
  • China’s ‘health silk road’ in Africa gets a boost with insulin and other pharma projects
  • China’s ‘health silk road’ in Africa gets a boost with insulin and other pharma projects

Recent Comments

No comments to show.

Welcome to World-Economist.com, your trusted source for in-depth analysis, expert insights, and the latest news on global finance and economics. Our mission is to provide readers with accurate, data-driven reports that shape the understanding of economic trends worldwide.

Latest Posts

Chinese scientists seek to unlock AI’s power to tackle real world problems

October 11, 2025

Asia eyes cheaper oil as Israel-Hamas ceasefire kindles hope for calm

October 11, 2025

Chinese local governments warned not to give AI access to sensitive data or state secrets

October 11, 2025

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Archives

  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • June 2024
  • October 2022
  • March 2022
  • July 2021
  • February 2021
  • January 2021
  • November 2019
  • April 2011
  • January 2011
  • December 2007
  • July 2007

Categories

  • AI & Tech
  • Asia
  • Banking
  • Business
  • Business
  • China
  • Climate
  • Computing
  • Economist Impact
  • Economist Intelligence
  • Economy
  • Editor's Choice
  • Europe
  • Europe
  • Featured
  • Featured Business
  • Featured Climate
  • Featured Health
  • Featured Science & Tech
  • Featured Travel
  • Finance & Economics
  • Health
  • Highlights
  • Markets
  • Middle East
  • Middle East & Africa
  • Middle East News
  • Most Viewed News
  • News Highlights
  • Other News
  • Politics
  • Russia
  • Science
  • Science & Tech
  • Social
  • Space Science
  • Sports
  • Sports Roundup
  • Tech
  • This week
  • Top Featured
  • Travel
  • Trending Posts
  • Ukraine Conflict
  • Uncategorized
  • US Politics
  • USA
  • World
  • World & Politics
  • World Economy
  • World News
© 2025 world-economist. Designed by world-economist.
  • Home
  • About Us
  • Advertise With Us
  • Contact Us
  • DMCA
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.